Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01652079
Title CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Brigham and Women's Hospital Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field